, Volume 1, Issue 3, pp 167-168
Date: 23 Aug 2012


Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

In 1990, outcomes of a clinical trial in which human growth hormone (HGH) was administered to elderly men who were otherwise ‘healthy for their ages’ showed that treatment was associated with increased muscle and decreased fat mass, especially in the abdomen.[1] These, in addition to less dramatic but nonetheless statistically significant changes, suggested that the age-related decline in HGH production contributes, at least in part, to progressive loss of a youthful phenotype. Conversely, the data suggested that some aspects of youth could be simulated in the aged by administration of exogenous HGH. If so, then it seemed logical to some that more global treatments intended to compensate for and oppose reduced endocrine system function and increased accumulation of cellular free radicals might be even more effective than HGH replacement alone. Enthusiasm for this concept resulted in the coining of the now popular term, ‘anti-ageing medicine’ and creation of an organisation called the A